HR
RARE icon

Howe & Rusling’s Ultragenyx Pharmaceutical RARE Stock Holding History

Howe & Rusling’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-298
Closed -$12K – 860
2022
Q3 		$12K Hold
298
– – ﹤0.01% 511
2022
Q2 		$18K Buy
298
+158
+113% +$9.72K ﹤0.01% 438
2022
Q1 		$10K Buy
+140
New +$9.74K ﹤0.01% 529
2016
Q3 		– Sell
-10
Closed – – 1105
2016
Q2 		$0 Hold
10
– – ﹤0.01% 1034
2016
Q1 		$1K Hold
10
– – ﹤0.01% 954
2015
Q4 		$1K Buy
10
+3
+43% +$300 ﹤0.01% 930
2015
Q3 		$1K Buy
+7
New +$801 ﹤0.01% 946

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Howe & Rusling's RARE Position: Q4 2022 in Review

Howe & Rusling sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 298 shares — an estimated $12K sold.

Howe & Rusling first reported a position in RARE in Q3 2015 and held it in 7 quarters. The position peaked at $18K in Q2 2022. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Howe & Rusling reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 298 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $12K.
  • Howe & Rusling first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 7 quarters.
  • Howe & Rusling's Ultragenyx Pharmaceutical position peaked at $18K in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.